OppenheimerFunds’s Aerie Pharmaceuticals AERI Stock Holding History

OppenheimerFunds’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-174,270	Closed	-$6.29M	–	1810
2018 Q4	$6.29M	Sell	174,270 -237,820	-58%	-$11.2M	0.01%	715
2018 Q3	$25.4M	Buy	412,090 +92,240	+29%	+$5.93M	0.03%	516
2018 Q2	$21.6M	Buy	319,850 +17,415	+6%	+$974K	0.03%	560
2018 Q1	$16.4M	Buy	302,435 +91,576	+43%	+$5.12M	0.02%	611
2017 Q4	$12.6M	Buy	210,859 +41,369	+24%	+$2.51M	0.02%	706
2017 Q3	$8.24M	Buy	+169,490	New	+$9.25M	0.01%	768

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

OppenheimerFunds's AERI Position: Q1 2019 in Review

OppenheimerFunds sold out of Aerie Pharmaceuticals (AERI) in Q1 2019, closing a stake of 174,270 shares — an estimated $6.29M sold.

OppenheimerFunds first reported a position in AERI in Q3 2017 and held it in 6 quarters. The position peaked at $25.4M in Q3 2018. 176 funds tracked by Wall St. Rank hold AERI as of Q1 2019.

OppenheimerFunds reported no remaining Aerie Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
OppenheimerFunds sold 174,270 Aerie Pharmaceuticals shares in Q1 2019, an estimated $6.29M.
OppenheimerFunds first reported a position in Aerie Pharmaceuticals in Q3 2017 and held it in 6 quarters.
OppenheimerFunds's Aerie Pharmaceuticals position peaked at $25.4M in Q3 2018.
176 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.